OR WAIT null SECS
February 02, 2024
Under a new collaboration, Lonza and Oxford Nanopore aim to commercialize a CGMP-validated test for advanced analysis of mRNA products.
The UK’s IRP increases flexibility and will help speed up product approvals and patient access to medicines.
The industry’s M&A activity is on the up and expected to continue to rise in 2024.
Agilent Technologies and Incyte have signed an agreement to collaborate on the development of companion diagnostics programs.
February 01, 2024
With the formation of the new R&D unit, Regeneron will assume full development and commercialization rights to 2seventy bio’s preclinical- and clinical-stage cell therapy pipeline.
The final guidance provides specific recommendations for CMC, pharmacology, toxicology, and clinical study design for CAR-T cell products.
An interview with Steffen Thirstrup, chief medical officer, European Medicines Agency (EMA).
January 31, 2024
The immune-resetting peptide, developed by Revolo Biotherapeutics, received positive results from its Phase IIb study.
The final guidance provides recommendations for developing gene therapy products incorporating genome editing of human somatic cells.
January 30, 2024
IMU Biosciences has secured £11.5 million in its Series A financing round.